Drug Shortage Report for EMGALITY

Last updated on 2024-03-08 History
Report ID 218192
Drug Identification Number 02491060
Brand name EMGALITY
Common or Proper name galcanezumab injection
Company Name ELI LILLY CANADA INC
Market Status MARKETED
Active Ingredient(s) GALCANEZUMAB
Strength(s) 120MG
Dosage form(s) SOLUTION
Route of administration SUBCUTANEOUS SUBCUTANEOUS
Packaging size Carton package containing one 120 mg/mL single-use prefilled syringe
ATC code N02CD
ATC description
Reason for shortage Demand increase for the drug.
Anticipated start date
Actual start date 2024-02-02
Estimated end date 2024-03-08
Actual end date 2024-03-07
Shortage status Resolved
Updated date 2024-03-08
Company comments The estimated end date represents projected availability at the main Lilly warehouse. For any questions or concerns, please contact our Customer Response Centre at 1-888-545-5972 (Monday-Friday, 9 a.m. to 5 p.m. Eastern Time, excluding holidays).
Health Canada comments
Tier 3 Status No
Contact Address EXCHANGE TOWER, 130 KING STREET WEST
TORONTO, ONTARIO
CANADA M5X 1B1
Company contact information Lilly Canada’s Customer Response Centre 1-888-545-5972.

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v7 2024-03-08 French Compare
v6 2024-03-08 English Compare
v5 2024-02-28 French Compare
v4 2024-02-28 English Compare
v3 2024-02-03 English Compare
v2 2024-02-02 French Compare
v1 2024-02-02 English Compare

Showing 1 to 7 of 7